scholarly journals Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals

2016 ◽  
Vol 7 (7) ◽  
pp. e179 ◽  
Author(s):  
Yumiko Nagao ◽  
Kanae Kimura ◽  
Yuji Kawahigashi ◽  
Michio Sata
2016 ◽  
Vol 10 (3) ◽  
pp. 617-622 ◽  
Author(s):  
Kenji Misaka ◽  
Takashi  Kishimoto ◽  
Yuji Kawahigashi ◽  
Michio Sata ◽  
Yumiko Nagao

Hepatitis C virus (HCV) is frequently associated with various extrahepatic manifestations such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one of the representative extrahepatic manifestations of HCV infection. Direct-acting antivirals (DAA) are highly effective and safe for the eradication of HCV. However, there is a lack of information regarding the association between HCV-associated OLP and interferon (IFN)-free DAA therapy. Herein, we present the case of a 60-year-old female who was diagnosed with OLP during routine periodontal treatment by a dentist. The patient was referred for hepatitis C treatment using IFN-free DAA, which resulted in the improvement of the symptoms of OLP. This case represents the safety and efficacy of IFN-free DAAs in patients with HCV-associated OLP. However, long-term follow-up studies are required to elucidate the therapeutic effects of this therapy in these patients.


2017 ◽  
Vol 11 (3) ◽  
pp. 701-710 ◽  
Author(s):  
Yumiko Nagao ◽  
Kazunori Nakasone ◽  
Tatsuji Maeshiro ◽  
Nao Nishida ◽  
Kanae Kimura ◽  
...  

Hepatitis C virus (HCV) infection is frequently associated with various extrahepatic manifestations, such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one such extrahepatic manifestation of HCV infection. Recently, direct-acting antivirals (DAA) have proved to be highly effective and safe for the eradication of HCV. Herein, we report a case of OLP accompanied by HCV-related hepatocellular carcinoma (HCC) that disappeared after liver transplantation and achievement of sustained virological response following interferon (IFN)-free treatment with ledipasvir (LDV) and sofosbuvir (SOF). The 50-year-old patient developed erosive OLP during IFN therapy, with hyperthyroidism at 53 years of age and HCC at 55 years. He received immunosuppressive drugs and IFN-free DAA treatment after liver transplantation at 60 years of age, which led to disappearance of the symptoms of OLP. The patient was treated safely and effectively with LDV/SOF, although it is not known whether the disappearance of OLP resulted from the eradication of HCV or the immunosuppressive therapy.


2020 ◽  
Vol 73 ◽  
pp. S617
Author(s):  
Marco Di Petrillo ◽  
Dario Di Stasio ◽  
Riccardo Nevola ◽  
Luca Rinaldi ◽  
Luigi Elio Adinolfi ◽  
...  

2018 ◽  
Vol 18 (3) ◽  
pp. 217-223 ◽  
Author(s):  
Alexandru Mester ◽  
Ondine Lucaciu ◽  
Lidia Ciobanu ◽  
Dragos Apostu ◽  
Aranka Ilea ◽  
...  

Oral lichen planus (OLP) is a chronic inflammatory disease characterized by the occurrence of multiple, symmetrical lesions in the oral cavity. Hepatitis C virus (HCV) infection has been suggested as an etiological factor in OLP. The purpose of this review was to summarize the current literature regarding the treatment of OLP in patients with HCV infection. An electronic search of the PubMed database was conducted until January 2018, using the following keywords: OLP, HCV, corticosteroids, retinoids, immunomodulatory agents, surgical interventions, photochemotherapy, laser therapy, interferon, ribavirin, and direct-acting antivirals. We selected the articles focusing on the clinical features and treatment management of OLP in patients with/without HCV infection. Topical corticosteroids are considered the first-line treatment in OLP. Calcineurin inhibitors or retinoids can be beneficial for recalcitrant OLP lesions. Systemic therapy should be used in the case of extensive and refractory lesions that involve extraoral sites. Surgical intervention is recommended for isolated lesions. In patients with HCV, monotherapy with interferon (IFN)-α may either improve, aggravate or trigger OLP lesions, while combined IFN-α and ribavirin therapy does not significantly influence the progression of lesions. Direct-acting antiviral (DAA) therapy appears to be a promising approach in patients with HCV-related OLP, as it can improve symptoms of both liver disease and OLP, with fewer side effects. Nevertheless, for clinical utility of DAAs in OLP patients, further studies with larger sample sizes, adequate treatment duration, and long term follow-up are required.


2016 ◽  
Vol 61 (3) ◽  
pp. 282-287 ◽  
Author(s):  
NA Alaizari ◽  
SA Al-Maweri ◽  
HM Al-Shamiri ◽  
B Tarakji ◽  
B Shugaa-Addin

2005 ◽  
Vol 34 (4) ◽  
pp. 204-208 ◽  
Author(s):  
M. Carrozzo ◽  
F. Brancatello ◽  
E. Dametto ◽  
P. Arduino ◽  
M. Pentenero ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document